Given the favourable results observed with the combination of trastuzumab, pertuzumab, and docetaxel in breast cancer, its efficacy was assessed in the single-arm phase II IFCT 1703-R2D2 trial in patients with HER2-mutant NSCLC who had previously been treated with platinum-based chemotherapy. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.